pargyline has been researched along with abiraterone in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, IC; Chen, MC; Hsieh, CM; Hsu, KC; Lai, RW; Lin, TE; Liou, JP; Nepali, K; Ojha, R; Pan, SL | 1 |
1 other study(ies) available for pargyline and abiraterone
| Article | Year |
|---|---|
Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.
Topics: Antineoplastic Agents; Histone Deacetylase Inhibitors; Histone Demethylases; Humans; Male; Pargyline; Prostatic Neoplasms | 2021 |